LIFE – BioTuesdays

Features

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Markets

HCW ups aTyr Pharma to buy; PT $13

H.C. Wainwright upgraded aTyr Pharma (NASDAQ:LIFE) to “buy” from “neutral” with a $13 price target, citing a “positive shift” at the company ahead of anticipated news flow. The stock closed at $3.81 on Aug. 14. Analyst...

August 17, 2020

Developments

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

aTyr Pharma (NASDAQ:LIFE) dosed the first patient in a Phase 2 study evaluating ATYR1923, an immunomodulator, in COVID-19 patients with severe respiratory complications. The study will enroll 30 COVID-19-positive...

June 15, 2020

Markets

HCW cuts aTyr Pharma to neutral and removes PT

H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...

March 27, 2020

Markets

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

November 5, 2019

Tag - LIFE

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

HCW ups aTyr Pharma to buy; PT $13

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

HCW cuts aTyr Pharma to neutral and removes PT

HCW starts aTyr Pharma at buy; PT $8

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter